当前位置:首页>产品中心>单抗/多抗>Anti-VEEV Spike glycoprotein Recombinant Nanobody |抗VEEV刺突糖蛋白纳米抗体(靶标:委内瑞拉马脑炎病毒刺突糖蛋白)

Anti-VEEV Spike glycoprotein Recombinant Nanobody |抗VEEV刺突糖蛋白纳米抗体(靶标:委内瑞拉马脑炎病毒刺突糖蛋白)

  • 货号:RB9TVK039043
  • 价格:面议
  • 点击:308
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Alpaca
克隆性Monoclonal
抗体亚型VHH-His
纯度>95% as determined by SDS-PAGE.
纯化方式Purified by Nickel column.
内毒素水平Please contact with the lab for this information.
应用ELISA
种属反应性Venezuelan equine encephalitis virus (VEEV)
靶标6K protein, Assembly protein E3, C, Capsid protein, Coat protein, E1 envelope glycoprotein, E2 envelope glycoprotein, EC:3.4.21.90, Precursor of protein E3/E2, Spike glycoprotein E1, Spike glycoprotei
储存缓冲液0.01M PBS pH 7.4
稳定性和储存Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
产品使用说明ELISA: 1:2000-1:20000
登录号P05674
背景信息

Structural polyprotein (Spike glycoprotein) is a ~138 kDa protein. Forms an icosahedral capsid with a T=4 symmetry composed of 240 copies of the capsid protein surrounded by a lipid membrane through which penetrate 80 spikes composed of trimers of E1-E2 heterodimers. The capsid protein binds to the viral RNA genome at a site adjacent to a ribosome binding site for viral genome translation following genome release. Possesses a protease activity that results in its autocatalytic cleavage from the nascent structural protein. Following its self-cleavage, the capsid protein transiently associates with ribosomes, and within several minutes the protein binds to viral RNA and rapidly assembles into icosahedric core particles. The resulting nucleocapsid eventually associates with the cytoplasmic domain of the spike glycoprotein E2 at the cell membrane, leading to budding and formation of mature virions.

备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 366
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 590
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 475
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 322
Anti-Isatuximab Neutralizing Recombinant Antibody |抗艾沙妥昔单抗中和重组抗体(靶标:艾沙妥昔单抗中和抗体) 285
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 552
Anti-Urelumab Non-Neutralizing Recombinant Antibody |抗乌瑞鲁单抗非中和重组抗体(靶标:乌瑞鲁单抗非中和抗体) 566
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 603
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 577
Anti-Urelumab Neutralizing Recombinant Antibody |抗乌瑞鲁单抗中和重组抗体(靶标:乌瑞鲁单抗中和抗体) 522
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 319
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 432
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 632
Anti-Risankizumab Neutralizing Recombinant Antibody |抗瑞莎珠单抗中和重组抗体(靶标:瑞莎珠单抗中和抗体) 316
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 510
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 406
Anti-Ranibizumab Non-Neutralizing Recombinant Antibody |抗雷珠单抗非中和重组抗体(靶标:雷珠单抗非中和抗体) 504
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 376
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 508
Anti-Ranibizumab Neutralizing Recombinant Antibody |抗雷珠单抗中和重组抗体(靶标:雷珠单抗中和抗体) 301
总计 33037 个记录,共 1652 页,当前第 1645 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00